Can a drug combo stop AML from coming back?
NCT ID NCT04062266
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tests whether a combination of two drugs, azacitidine and venetoclax, can help keep acute myeloid leukemia (AML) in remission after initial treatment. The study enrolls 50 adults whose AML is in first remission but who are not ready for a stem cell transplant. Participants receive the drugs as maintenance therapy, and researchers track how long they stay relapse-free and monitor for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
azacitidine and venetoclax
What this could lead to
If successful, this combination could help keep AML in remission longer, delaying or preventing relapse after initial treatment.
What could go wrong
This is a small, early-phase (phase II) study with only 50 participants. The drugs may cause serious side effects, and it is not yet known if they will improve long-term outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States